![Patrick Merat](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrick Merat
Plus aucun poste en cours
Profil
Patrick Merat worked as a Director at Tercica, Inc.
Anciens postes connus de Patrick Merat
Sociétés | Poste | Fin |
---|---|---|
Tercica, Inc.
![]() Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Directeur/Membre du Conseil | 03/02/2014 |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 1 |
---|---|
Tercica, Inc.
![]() Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |